Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$4.15 – $5.33
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $612.9M | $686.3M | $629.5M | $718.7M | $718.6M | $785.7M | $854.9M | $963.6M |
| Cost of revenue | $226.1M | $247.6M | $238.3M | $263.3M | $278.9M | $300.1M | $320.2M | $403.0M |
| Gross profit | $386.8M | $438.6M | $391.2M | $455.4M | $439.7M | $485.6M | $534.7M | $560.6M |
| Gross margin | 63.1% | 63.9% | 62.1% | 63.4% | 61.2% | 61.8% | 62.5% | 58.2% |
| R&D | $31.4M | $31.3M | $31.0M | $31.7M | $34.0M | $38.1M | $40.8M | $41.0M |
| Operating income | $78.9M | $98.6M | $22.3M | $97.3M | $64.8M | $89.4M | $112.8M | $129.4M |
| EBITDA | $118.5M | $144.0M | $87.0M | $144.8M | $120.0M | $146.1M | $169.8M | $189.9M |
| Net income | $79.8M | $66.0M | $6.2M | $64.0M | $42.5M | $58.4M | $68.3M | $86.5M |
| Net margin | 13.0% | 9.6% | 1.0% | 8.9% | 5.9% | 7.4% | 8.0% | 9.0% |
| EPS (diluted) | 0.19 | 0.16 | 0.02 | 0.15 | 0.10 | 0.14 | 0.16 | 0.20 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.0B | $0.23 | $0.23–$0.23 | 1 |
| 2027 | $1.1B | $0.27 | $0.26–$0.27 | 1 |
| 2028 | $1.2B | $0.31 | $0.30–$0.31 | 1 |
| 2029 | $1.3B | $0.34 | $0.34–$0.34 | 1 |
Forward consensus · source: Financial Modeling Prep
EMBLA MEDICAL
No one on the platform currently holds OSSFF.
No tracked institution reports a position in OSSFF as of their last filing.
No one on the platform has traded OSSFF yet.
| $1.9B |
| — |
| HBMHFHBM Holdings Limited | $1.56 | +0.00% | $1.3B | — |
| MEDGFMedacta Group S.A. | $83.91 | +0.00% | $1.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 24.3× earnings vs its 30.7× historical median P/E.
Fair value ≈ $5.24 · price $4.15 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.